Get the Stockscreener App
1.08
6.09%
-0.07
After Hours:
1.10
0.02
+1.85%
ABVC BioPharma Inc stock is currently priced at $1.08, with a 24-hour trading volume of 413.73K.
It has seen a -6.09% decreased in the last 24 hours and a -16.28% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.14 pivot point. If it approaches the $1.07 support level, significant changes may occur.
Previous Close:
$1.15
Open:
$1.15
24h Volume:
413.73K
Market Cap:
$11.41M
Revenue:
$152.40K
Net Income/Loss:
$-10.52M
P/E Ratio:
-0.2784
EPS:
-3.88
Net Cash Flow:
$-4.26M
1W Performance:
-23.94%
1M Performance:
-16.28%
6M Performance:
-7.69%
1Y Performance:
+47.95%
1D Range:
$1.07
$1.15
52W Range:
$0.3329
$6.87
ABVC BioPharma Inc Stock (ABVC) Company Profile
Name
ABVC BioPharma Inc
Sector
Industry
Phone
510 668 0881
Address
44370 Old Warm Springs Boulevard, Fremont
ABVC BioPharma Inc Stock (ABVC) Latest News
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
GlobeNewswire Inc.
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
GlobeNewswire Inc.
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
GlobeNewswire Inc.
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
GlobeNewswire Inc.
Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why Resources Connection Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Benzinga
ABVC BioPharma Inc Stock (ABVC) Financials Data
ABVC BioPharma Inc (ABVC) Revenue 2024
ABVC reported a revenue (TTM) of $152.40 thousand for the quarter ending December 31, 2023, a -84.29% decline year-over-year.
ABVC BioPharma Inc (ABVC) Net Income 2024
ABVC net income (TTM) was -$10.52 million for the quarter ending December 31, 2023, a +35.97% increase year-over-year.
ABVC BioPharma Inc (ABVC) Cash Flow 2024
ABVC recorded a free cash flow (TTM) of -$4.26 million for the quarter ending December 31, 2023, a +43.38% increase year-over-year.
ABVC BioPharma Inc (ABVC) Earnings per Share 2024
ABVC earnings per share (TTM) was -$2.4931 for the quarter ending December 31, 2023, a +52.15% growth year-over-year.
About ABVC BioPharma Inc
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
1.62%
0.15%
Cap:
|
Volume (24h):